SecProbe.io

March 20, 2019
Joseph Oliveto
Chief Executive Officer
Milestone Pharmaceuticals Inc.
6000 Fairview Road, Suite 1200
Charlotte, NC 28210-2252
Re:Milestone Pharmaceuticals Inc.
Amendment No. 2 to Draft Registration Statement on Form S-1
Filed March 15, 2019
CIK 0001408443
Dear Mr. Oliveto:
            We have reviewed your amended draft registration statement and have the following
comment.
            Please respond to this letter by providing the requested information and either submitting
an amended draft registration statement or publicly filing your registration statement on
EDGAR.  If you do not believe our comment applies to your facts and circumstances or do not
believe an amendment is appropriate, please tell us why in your response.
            After reviewing the information you provide in response to the comment and your
amended draft registration statement or filed registration statement, we may have additional
comments.
Amendment No. 2 to Draft Registration Statement on Form S-1
PSVT, page 2
1.We note the disclosure that was added on page 2 in response to prior comment 2. Please
also include the findings from your survey that after the first year of diagnosis the
percentage of patients with PSVT episodes lasting longer than 10 minutes and the
percentage visiting the emergency department for treatment decreases to approximately
one-third of those surveyed.

 FirstName LastNameJoseph Oliveto
 Comapany NameMilestone Pharmaceuticals Inc.
 March 20, 2019 Page 2
 FirstName LastName
Joseph Oliveto
Milestone Pharmaceuticals Inc.
March 20, 2019
Page 2
            You may contact William Demarest at (202) 551-3432 or Yolanda Trotter at (202) 551-
3472 if you have questions regarding comments on the financial statements and related
matters.  Please contact Chris Edwards at (202) 551-6761 or Liz Walsh at (202) 551-3696 with
any other questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc:       Jaime L. Chase